azomycin has been researched along with linezolid in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 17 (47.22) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Chauffour, A; Jarlier, V; Ji, B | 1 |
| Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C | 1 |
| Nau, JY | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Cox, H; Daniels, C; Furin, J; Lessem, E; McKenna, L; Mitnick, CD; Mosidi, T; Reed, C; Seaworth, B; Stillo, J; Tisile, P; von Delft, D | 1 |
| Caminero, JA; Scardigli, A | 1 |
| Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T | 1 |
| Cohen, J | 1 |
| Brzezinski, A; Milstein, M; Mitnick, CD; Varaine, F | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Dass, R; Hettle, R; Wirth, D | 1 |
| Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z | 1 |
| Borroni, E; Cirillo, DM; Crook, DW; Cugnata, F; Davies, TJ; Fowler, PW; Gibertoni Cruz, AL; Grazian, C; Hoosdally, SJ; Peto, TEA; Rancoita, PMV; Walker, TM | 1 |
| Choi, H; Kim, KJ; Lee, SH; Yang, JS | 1 |
| Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ | 1 |
| Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
| Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH | 1 |
| Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM | 1 |
| Burki, T | 1 |
| Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH | 1 |
| Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H | 1 |
| Cooper, CB; Denny, WA; Ding, CZ; Ding, J; He, S; Lu, Y; Lynch, AS; Ma, Z; Upton, AM; Wan, D; Wang, X; Yuan, Y; Zhang, Q; Zhuang, Z | 1 |
| Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R | 1 |
| Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD | 1 |
| Acquah, R; Daniels, J; Furin, J; Loveday, M; Mohr-Holland, E; Mudaly, V; Reuter, A | 1 |
| de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A | 1 |
| Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A | 1 |
| Howell, P; Mvuna, N; Olugbosi, M; Upton, C | 1 |
| Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W | 1 |
| Cook-Scalise, S; Edo, P; Gebhard, A; Juneja, S; Kadyrov, A; Lawanson, A; Malhotra, S; Mambetova, E; Mulder, C; Pambudi, I; Rupert, S; Setiawan, E; Sohn, H; Sugiharto, J; Useni, S; van den Hof, S | 1 |
| Adenov, M; Adnan, S; Ahmed, S; Bastard, M; Coutisson, S; Danielyan, N; Franke, MF; Hewison, C; Huerga, H; Islam, S; Janmohamed, A; Kamene Kimenye, M; Karakozian, H; Khan, P; Khan, U; Kholikulov, B; Kirakosyan, O; Krisnanda, A; Kumsa, A; Lachenal, N; Leblanc, G; Lecca, L; Mamsa, S; Melikyan, N; Mitnick, CD; Nkuebe, M; Osso, E; Padayachee, S; Rich, ML; Seung, KJ; Thit, P; Varaine, F | 1 |
| Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L | 1 |
| Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R | 1 |
| Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P | 1 |
| Bahr, M; Brosnan, MK; Chen, X; Dannals, RF; De Jesus, P; Erice, C; Flavahan, K; Holt, DP; Jain, SK; Kim, J; Lodge, MA; Mota, F; Ordonez, AA; Peloquin, CA; Ruiz-Bedoya, CA; Tucker, EW | 1 |
| Betoudji, F; Converse, PJ; Fotouhi, N; Lee, J; Li, SY; Mdluli, K; Nuermberger, EL; Upton, A | 1 |
7 review(s) available for azomycin and linezolid
| Article | Year |
|---|---|
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
Topics: Antitubercular Agents; Compassionate Use Trials; Diarylquinolines; Health Services Accessibility; Humans; Linezolid; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Vulnerable Populations | 2015 |
(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
Topics: Administration, Oral; Antitubercular Agents; Clinical Trials, Phase III as Topic; Diarylquinolines; Evidence-Based Medicine; Humans; Linezolid; Needles; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant | 2016 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant | 2020 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
5 trial(s) available for azomycin and linezolid
| Article | Year |
|---|---|
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
24 other study(ies) available for azomycin and linezolid
| Article | Year |
|---|---|
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines | 2006 |
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors | 2006 |
[Some new antitubercular agents].
Topics: Acetamides; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Oxazoles; Oxazolidinones; Quinolines | 2008 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |
Easier cure for resistant TB.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Baltimore; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; South Africa; Sputum; Treatment Outcome | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Topics: Adult; Antitubercular Agents; Clinical Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Female; Germany; Humans; Linezolid; Male; Nitroimidazoles; Observational Studies as Topic; Oxazoles; Quality-Adjusted Life Years; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2017 |
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reproducibility of Results; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2018 |
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Topics: Antitubercular Agents; Diarylquinolines; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant | 2018 |
BPaL approved for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Drug Therapy, Combination; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria.
Topics: Antitubercular Agents; Bacteria, Anaerobic; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant | 2020 |
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Recurrence; Tuberculosis | 2021 |
Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients.
Topics: Adult; Antitubercular Agents; Child Health; Child, Preschool; Diarylquinolines; Female; Humans; Infant; Infant Health; Linezolid; Nitroimidazoles; Oxazoles; Pregnancy; Pregnancy Outcome; Pregnant Women; South Africa; Tuberculosis, Multidrug-Resistant; Young Adult | 2021 |
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant | 2021 |
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Nitroimidazoles | 2022 |
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Topics: Antitubercular Agents; Diarylquinolines; Electrolytes; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Topics: Antitubercular Agents; Clofazimine; Cohort Studies; Diarylquinolines; Electrolytes; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
Dynamic
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Humans; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Rabbits; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant | 2022 |
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Nitroimidazoles; Oxazolidinones; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |